| Title |
Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations
|
|---|---|
| Published in |
Advances in Therapy, August 2014
|
| DOI | 10.1007/s12325-014-0148-2 |
| Pubmed ID | |
| Authors |
Alfonso Berrocal, Luis Cabañas, Enrique Espinosa, Ricardo Fernández-de-Misa, Salvador Martín-Algarra, José Carlos Martínez-Cedres, Luis Ríos-Buceta, José Luis Rodríguez-Peralto |
| Abstract |
The incidence of malignant melanoma is increasing worldwide. In Spain, its incidence is increasing faster than any other cancer type, with a 5-year survival rate of about 85%. The impact and characteristics of malignant melanoma in the Spanish population can be ascertained from the national melanoma registry of the Academia Española de Dermatología y Venereología. This review presents consensus group recommendations for the diagnosis, staging and treatment of malignant melanoma in Spain. Incidence and mortality are discussed, as well as evaluation of various prevention and treatment strategies. Prognostic factors, such as BRAF and C-KIT mutations, which are expected to become routine staging procedures over the next few years, are outlined, especially in relation to treatment options. The use of recently approved targeted agents such as ipilimumab, a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitor, and vemurafenib, a BRAF inhibitor, in metastatic disease are also discussed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 1 | 2% |
| Unknown | 44 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 13% |
| Student > Bachelor | 6 | 13% |
| Student > Doctoral Student | 5 | 11% |
| Other | 4 | 9% |
| Student > Master | 4 | 9% |
| Other | 10 | 22% |
| Unknown | 10 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 42% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Agricultural and Biological Sciences | 3 | 7% |
| Immunology and Microbiology | 2 | 4% |
| Nursing and Health Professions | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 15 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2021.
All research outputs
#6,941,350
of 22,760,687 outputs
Outputs from Advances in Therapy
#619
of 2,337 outputs
Outputs of similar age
#68,055
of 235,583 outputs
Outputs of similar age from Advances in Therapy
#5
of 21 outputs
Altmetric has tracked 22,760,687 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 2,337 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,583 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.